The Cure Rare Disease Foundation is Trying to Change the “One Size Fits All” Approach Toward Treatment

The Cure Rare Disease Foundation The Cure Rare Disease Foundation's mission is to increase collaborative efforts between researchers in order to accelerate the development of customized therapies for individuals living with…

Continue Reading
After Issues With Adverse Events, the Future of This Experimental Duchenne Muscular Dystrophy Drug Remains Unclear
<a href="https://pixabay.com/users/Parentingupstream/">Parentingupstream</a> / Pixabay

After Issues With Adverse Events, the Future of This Experimental Duchenne Muscular Dystrophy Drug Remains Unclear

According to a story from BioSpace, a Phase 1/2 clinical trial testing SGT-001, an investigational treatment for Duchenne muscular dystrophy, has been plagued by problems with side effects and adverse…

Continue Reading
After Issues With Adverse Events, the Future of This Experimental Duchenne Muscular Dystrophy Drug Remains Unclear
<a href="https://pixabay.com/users/Parentingupstream/">Parentingupstream</a> / Pixabay

After Issues With Adverse Events, the Future of This Experimental Duchenne Muscular Dystrophy Drug Remains Unclear

According to a story from BioSpace, a Phase 1/2 clinical trial testing SGT-001, an investigational treatment for Duchenne muscular dystrophy, has been plagued by problems with side effects and adverse…

Continue Reading
Muscular Dystrophy Association to Host First Annual Combined Conference
Hundreds of people living with narcolepsy gathered at the NN's 2015 Conference to make friends and learn something new. Source: Narcolepsy Network

Muscular Dystrophy Association to Host First Annual Combined Conference

A recent publication from Charcot-Marie-Tooth News announced that this year, for the first time ever, the Muscular Dystrophy Association will be hosting its annual clinical conferences at the same event…

Continue Reading
Company Announces Plans to File for Conditional Marketing for Duchenne Muscular Dystrophy Drug in the EU
<a href="https://pixabay.com/users/fernandozhiminaicela/">fernandozhiminaicela</a> / Pixabay

Company Announces Plans to File for Conditional Marketing for Duchenne Muscular Dystrophy Drug in the EU

According to a story from Market Screener, the specialty pharmaceutical company Santhera Pharmaceuticals recently released an announcement in which the company revealed its intent to file for Conditional Marketing Authorization…

Continue Reading
Close Menu